Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma

Allan Norman Krutchik, A. U. Buzdar, G. R. Blumenschein, J. G. Sinkovics

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Nineteen patients resistant to an adriamycin-containing regimen were treated with 4 days of tericin B and the same adriamycin-containing chemotherapy regimen that had been given without amphotericin B. Of the 14 evaluable patients (11 with breast carcinoma and three with sarcoma), one patient with breast carcinoma achieved a partial remission and a second patient with breast carcinoma remained stable. All other patients developed progressive disease. Both hematologic and nonhematologic toxicity were significantly increased when amphotericin B was added to chemotherapy.

Original languageEnglish (US)
Pages (from-to)1565-1567
Number of pages3
JournalCancer Treatment Reports
Volume62
Issue number10
StatePublished - Dec 1 1978

Fingerprint

Amphotericin B
Combination Drug Therapy
Sarcoma
Breast Neoplasms
Doxorubicin
Therapeutics
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma. / Krutchik, Allan Norman; Buzdar, A. U.; Blumenschein, G. R.; Sinkovics, J. G.

In: Cancer Treatment Reports, Vol. 62, No. 10, 01.12.1978, p. 1565-1567.

Research output: Contribution to journalArticle

@article{414482e174644514b045091723a641e1,
title = "Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma",
abstract = "Nineteen patients resistant to an adriamycin-containing regimen were treated with 4 days of tericin B and the same adriamycin-containing chemotherapy regimen that had been given without amphotericin B. Of the 14 evaluable patients (11 with breast carcinoma and three with sarcoma), one patient with breast carcinoma achieved a partial remission and a second patient with breast carcinoma remained stable. All other patients developed progressive disease. Both hematologic and nonhematologic toxicity were significantly increased when amphotericin B was added to chemotherapy.",
author = "Krutchik, {Allan Norman} and Buzdar, {A. U.} and Blumenschein, {G. R.} and Sinkovics, {J. G.}",
year = "1978",
month = "12",
day = "1",
language = "English (US)",
volume = "62",
pages = "1565--1567",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma

AU - Krutchik, Allan Norman

AU - Buzdar, A. U.

AU - Blumenschein, G. R.

AU - Sinkovics, J. G.

PY - 1978/12/1

Y1 - 1978/12/1

N2 - Nineteen patients resistant to an adriamycin-containing regimen were treated with 4 days of tericin B and the same adriamycin-containing chemotherapy regimen that had been given without amphotericin B. Of the 14 evaluable patients (11 with breast carcinoma and three with sarcoma), one patient with breast carcinoma achieved a partial remission and a second patient with breast carcinoma remained stable. All other patients developed progressive disease. Both hematologic and nonhematologic toxicity were significantly increased when amphotericin B was added to chemotherapy.

AB - Nineteen patients resistant to an adriamycin-containing regimen were treated with 4 days of tericin B and the same adriamycin-containing chemotherapy regimen that had been given without amphotericin B. Of the 14 evaluable patients (11 with breast carcinoma and three with sarcoma), one patient with breast carcinoma achieved a partial remission and a second patient with breast carcinoma remained stable. All other patients developed progressive disease. Both hematologic and nonhematologic toxicity were significantly increased when amphotericin B was added to chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0018234778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018234778&partnerID=8YFLogxK

M3 - Article

C2 - 709557

AN - SCOPUS:0018234778

VL - 62

SP - 1565

EP - 1567

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 10

ER -